title: Metabolic effects of GH antagonism in patients with acromegaly.
abstract: Pegvisomant is a growth hormone (GH) receptor antagonist that represents a major advance in the treatment of acromegaly. Initial results with pegvisomant indicate this novel form of therapy to be the most effective treatment available for achieving biochemical disease control as ascertained by circulating IGF-I.
authors.affiliation: Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK. peter.trainer@man.ac.uk
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Trainer
mesh_terms: D000172:Acromegaly / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D019382:Human Growth Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors*
chemical_list: D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; C406545:pegvisomant